Correlates of treatment patterns among youth with type 2 diabetes
- PMID: 24026554
- PMCID: PMC3867996
- DOI: 10.2337/dc13-1124
Correlates of treatment patterns among youth with type 2 diabetes
Abstract
OBJECTIVE To describe treatment regimens in youth with type 2 diabetes and examine associations between regimens, demographic and clinical characteristics, and glycemic control. RESEARCH DESIGN AND METHODS This report includes 474 youth with a clinical diagnosis of type 2 diabetes who completed a SEARCH for Diabetes in Youth study visit. Diabetes treatment regimen was categorized as lifestyle alone, metformin monotherapy, any oral hypoglycemic agent (OHA) other than metformin or two or more OHAs, insulin monotherapy, and insulin plus any OHA(s). Association of treatment with demographic and clinical characteristics (fasting C-peptide [FCP], diabetes duration, and self-monitoring of blood glucose [SMBG]), and A1C was assessed by χ(2) and ANOVA. Multiple linear regression models were used to evaluate independent associations of treatment regimens and A1C, adjusting for demographics, diabetes duration, FCP, and SMBG. RESULTS Over 50% of participants reported treatment with metformin alone or lifestyle. Of the autoantibody-negative youth, 40% were on metformin alone, while 33% were on insulin-containing regimens. Participants on metformin alone had a lower A1C (7.0 ± 2.0%, 53 ± 22 mmol/mol) than those on insulin alone (9.2 ± 2.7%, 77 ± 30 mmol/mol) or insulin plus OHA (8.6 ± 2.6%, 70 ± 28 mmol/mol) (P < 0.001). These differences remained significant after adjustment (7.5 ± 0.3%, 58 ± 3 mmol/mol; 9.1 ± 0.4%, 76 ± 4 mmol/mol; and 8.6 ± 0.4%, 70 ± 4 mmol/mol) (P < 0.001) and were more striking in those with diabetes for ≥2 years (7.9 ± 2.8, 9.9 ± 2.8, and 9.8 ± 2.6%). Over one-half of those on insulin-containing therapies still experience treatment failure (A1C ≥8%, 64 mmol/mol). CONCLUSIONS Approximately half of youth with type 2 diabetes were managed with lifestyle or metformin alone and had better glycemic control than individuals using other therapies. Those with longer diabetes duration in particular commonly experienced treatment failures, and more effective management strategies are needed.
References
- 
    - Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89–94 - PubMed
 
- 
    - Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care 2007;30:790–794 - PubMed
 
Publication types
MeSH terms
Substances
Grants and funding
- U01 DP000247/DP/NCCDPHP CDC HHS/United States
- U01 DP000245/DP/NCCDPHP CDC HHS/United States
- U48/CCU419249/PHS HHS/United States
- M01 RR000069/RR/NCRR NIH HHS/United States
- U18DP002708-01/DP/NCCDPHP CDC HHS/United States
- U18 DP002714/DP/NCCDPHP CDC HHS/United States
- U01 DP000248/DP/NCCDPHP CDC HHS/United States
- U01 DP000244/DP/NCCDPHP CDC HHS/United States
- P30 DK57516/DK/NIDDK NIH HHS/United States
- U48/CCU519239/PHS HHS/United States
- U18DP002710-01/DP/NCCDPHP CDC HHS/United States
- UL1 TR001082/TR/NCATS NIH HHS/United States
- UL1 TR000077/TR/NCATS NIH HHS/United States
- U01 DP000250/DP/NCCDPHP CDC HHS/United States
- P30 DK057516/DK/NIDDK NIH HHS/United States
- HIR 10-001/HX/HSRD VA/United States
- 1U18DP002709/DP/NCCDPHP CDC HHS/United States
- U48/CCU819241-3/PHS HHS/United States
- U18 DP002710/DP/NCCDPHP CDC HHS/United States
- U18DP002714/DP/NCCDPHP CDC HHS/United States
- U48/CCU919219/PHS HHS/United States
- M01 RR000037/RR/NCRR NIH HHS/United States
- U58CCU919256/PHS HHS/United States
- 1UL1RR026314-01/RR/NCRR NIH HHS/United States
- U18DP000247-06A1/DP/NCCDPHP CDC HHS/United States
- UL1 RR029882/RR/NCRR NIH HHS/United States
- M01 RR00069/RR/NCRR NIH HHS/United States
- U58/CCU019235-4/PHS HHS/United States
- U18 DP002709/DP/NCCDPHP CDC HHS/United States
- U01 DP000246/DP/NCCDPHP CDC HHS/United States
- U01 DP000254/DP/NCCDPHP CDC HHS/United States
- UL1 RR026314/RR/NCRR NIH HHS/United States
- U18 DP002708/DP/NCCDPHP CDC HHS/United States
- UL1RR029882/RR/NCRR NIH HHS/United States
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
 
        